案例报告:在复发性和耐火性外骨髓性多发性骨髓瘤中,双重向的BCMA和CS1CAR-T细胞免疫疗法

Xiangjun Shi1, Yue Wu2, Xingchen Yao2

  • 1Department of Rheumatology and Immunology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Frontiers in immunology
|August 14, 2024
PubMed
概括

针对BCMA和CS1的CAR-T细胞疗法在治疗多发性骨髓瘤的外骨髓性复发时表现出有限的疗效. 瘤中MYBL2表达的增加可能会阻碍治疗的成功,这表明需要新的治疗策略.